-
Je něco špatně v tomto záznamu ?
Baseline serum levels of multiple cytokines and adhesion molecules in patients with acute myeloid leukemia: results of a pivotal trial
T. Kupsa, M. Vasatova, I. Karesova, P. Zak, JM. Horacek,
Jazyk angličtina Země Ukrajina
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
25537219
Knihovny.cz E-zdroje
- MeSH
- akutní myeloidní leukemie krev farmakoterapie genetika patologie MeSH
- chemorezistence MeSH
- cytokiny krev MeSH
- dospělí MeSH
- indukce remise MeSH
- lidé středního věku MeSH
- lidé MeSH
- molekuly buněčné adheze krev MeSH
- mutace MeSH
- senioři MeSH
- translokace genetická MeSH
- věkové faktory MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
AIM: Evaluation of serum levels of 17 cytokines and 5 adhesion molecules in patients with newly diagnosed acute myeloid leukemia (AML) using biochip array technology. We searched for links between baseline levels and age, hyperleukocytosis, secondary origin of AML, resistance to induction therapy with cytarabine and daunorubicin and standard risk stratification according to cytogenetics and molecular genetics. METHODS: We evaluated the sera of 51 consecutive patients. Serum samples were analyzed by biochip based immunoassays on the Evidence Investigator analyzer. T-tests were used for statistical analysis. RESULTS: We found that higher age is associated with lower levels of interleukin (IL)-12. Patients with secondary disease were older, had higher levels of EGF and IL-7, and lower levels of E-selectin, IL-12 and IL-13. In hyperleukocytosis, the levels of IL-1β, IL-2, TNF-α, VCAM-1, ICAM-1, -E-selectin and L-selectin were increased, whereas levels of IFN-γ and MCP-1 were decreased. In patients who failed to achieve complete remission after induction therapy, we found lower E-selectin and P-selectin levels. High risk patients had lower levels of IFN-γ. CONCLUSION: Some leukemic cell subpopulations have the ability to produce cytokines that modulate the microenvironment by inducing inflammation. This causes endothelial cells to be activated and overexpress adhesion molecules. Hyperleukocytosis and secondary origin of the disease are the major factors influencing the cytokine and adhesion molecule profile in newly diagnosed AML patients.
- 000
- 00000naa a2200000 a 4500
- 001
- bmc15031554
- 003
- CZ-PrNML
- 005
- 20151012102311.0
- 007
- ta
- 008
- 151005s2014 un f 000 0|eng||
- 009
- AR
- 035 __
- $a (PubMed)25537219
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a un
- 100 1_
- $a Kupsa, T $u Department of Military Internal Medicine and Military Hygiene, University of Defence, Faculty of Military Health Sciences, Hradec Kralove 50001, Czech Republic.
- 245 10
- $a Baseline serum levels of multiple cytokines and adhesion molecules in patients with acute myeloid leukemia: results of a pivotal trial / $c T. Kupsa, M. Vasatova, I. Karesova, P. Zak, JM. Horacek,
- 520 9_
- $a AIM: Evaluation of serum levels of 17 cytokines and 5 adhesion molecules in patients with newly diagnosed acute myeloid leukemia (AML) using biochip array technology. We searched for links between baseline levels and age, hyperleukocytosis, secondary origin of AML, resistance to induction therapy with cytarabine and daunorubicin and standard risk stratification according to cytogenetics and molecular genetics. METHODS: We evaluated the sera of 51 consecutive patients. Serum samples were analyzed by biochip based immunoassays on the Evidence Investigator analyzer. T-tests were used for statistical analysis. RESULTS: We found that higher age is associated with lower levels of interleukin (IL)-12. Patients with secondary disease were older, had higher levels of EGF and IL-7, and lower levels of E-selectin, IL-12 and IL-13. In hyperleukocytosis, the levels of IL-1β, IL-2, TNF-α, VCAM-1, ICAM-1, -E-selectin and L-selectin were increased, whereas levels of IFN-γ and MCP-1 were decreased. In patients who failed to achieve complete remission after induction therapy, we found lower E-selectin and P-selectin levels. High risk patients had lower levels of IFN-γ. CONCLUSION: Some leukemic cell subpopulations have the ability to produce cytokines that modulate the microenvironment by inducing inflammation. This causes endothelial cells to be activated and overexpress adhesion molecules. Hyperleukocytosis and secondary origin of the disease are the major factors influencing the cytokine and adhesion molecule profile in newly diagnosed AML patients.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a věkové faktory $7 D000367
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a molekuly buněčné adheze $x krev $7 D015815
- 650 _2
- $a cytokiny $x krev $7 D016207
- 650 _2
- $a chemorezistence $7 D019008
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a akutní myeloidní leukemie $x krev $x farmakoterapie $x genetika $x patologie $7 D015470
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a mutace $7 D009154
- 650 _2
- $a indukce remise $7 D012074
- 650 _2
- $a translokace genetická $7 D014178
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Vasatova, M $u Institute of Clinical Biochemistry and Diagnostics, University Hospital, Hradec Kralove 50005, Czech Republic.
- 700 1_
- $a Karesova, I $u Institute of Clinical Biochemistry and Diagnostics, University Hospital, Hradec Kralove 50005, Czech Republic.
- 700 1_
- $a Zak, P $u 4th Department of Internal Medicine - Hematology, University Hospital and Charles University, Faculty of Medicine, Hradec Kralove 50005, Czech Republic.
- 700 1_
- $a Horacek, J M $u Department of Military Internal Medicine and Military Hygiene, University of Defence, Faculty of Military Health Sciences, Hradec Kralove 50001, Czech Republic.
- 773 0_
- $w MED00174402 $t Experimental oncology $x 1812-9269 $g Roč. 36, č. 4 (2014), s. 252-7
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/25537219 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20151005 $b ABA008
- 991 __
- $a 20151012102500 $b ABA008
- 999 __
- $a ok $b bmc $g 1092430 $s 914680
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2014 $b 36 $c 4 $d 252-7 $i 1812-9269 $m Experimental oncology $n Exp Oncol $x MED00174402
- LZP __
- $a Pubmed-20151005